Literature DB >> 19885927

RBSP3 is frequently altered in premalignant cervical lesions: clinical and prognostic significance.

Sraboni Mitra1, Dipanjana Mazumder Indra, Nilanjana Bhattacharya, Ratnesh K Singh, Partha S Basu, Ranajit K Mondal, Anup Roy, Eugene R Zabarovsky, Susanta Roychoudhury, Chinmay K Panda.   

Abstract

To understand the importance of frequent deletion of 3p22.3 in cervical carcinogenesis, alterations (deletion/methylation/expression) of the candidate genes STAC, MLH1, ITGA9, and RBSP3, located in the region, were analyzed in 24 cervical intraepithelial neoplasia (CIN) and 137 uterine cervical carcinoma (CACX) samples. In CIN, RBSP3 deletion (48%) and methylation (26%) were high compared with the other genes (4-9%). In CACX, alterations of these genes were as follows: deletion: STAC (54%) > MLH1 (46%) > RBSP3 (45%) > ITGA9 (41%), methylation: RBSP3 (25%) > ITGA9 (24%) > STAC (19%) > MLH1 (13%). Overall, alterations of RBSP3 showed association with CIN, whereas for STAC and MLH1, this frequency increased significantly from CIN --> Stage I/II and for ITGA9 from CIN --> Stage I/II and also from Stage I/II --> Stage III/IV. Quantitative mRNA expression analysis showed differential reduced expression of these genes in CACX concordant to their molecular alterations. The more active RBSP3B splice variant was underexpressed in CACX. RB1 was infrequently deleted in CACX. Concordance was seen between (i) inactivation of RBSP3 and intense p-RB1 nuclear immunostaining and (ii) low/absence of MLH1 expression and its molecular alterations in CACX. In normal cervical epithelium, p-RB1 immunostaining was low in differentiated cells, whereas MLH1 staining was seen in both nucleus and cytoplasm irrespective of differentiation stage. Alterations of the genes were significantly associated with poor prognosis. High parity (>or=5)/early sexual debut (<or=19 years) coupled with RBSP3 alterations/RB1 deletion predicted worst prognosis. Thus, inactivation of RBSP3 might be one of the early events in cervical carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19885927     DOI: 10.1002/gcc.20726

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  13 in total

1.  Alterations of ATM and CADM1 in chromosomal 11q22.3-23.2 region are associated with the development of invasive cervical carcinoma.

Authors:  Dipanjana Mazumder Indra; Sraboni Mitra; Anup Roy; Ranajit Kumar Mondal; Partha Sarathi Basu; Susanta Roychoudhury; Runu Chakravarty; Chinmay Kumar Panda
Journal:  Hum Genet       Date:  2011-06-05       Impact factor: 4.132

2.  Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors.

Authors:  Luydmila A Mostovich; Tatiana Y Prudnikova; Aleksandr G Kondratov; Dina Loginova; Pavel V Vavilov; Valentina I Rykova; Sergei V Sidorov; Tatiana V Pavlova; Vladimir I Kashuba; Eugene R Zabarovsky; Elvira V Grigorieva
Journal:  Cell Adh Migr       Date:  2011 Sep-Oct       Impact factor: 3.405

3.  Simultaneous down-regulation of tumor suppressor genes RBSP3/CTDSPL, NPRL2/G21 and RASSF1A in primary non-small cell lung cancer.

Authors:  Vera N Senchenko; Ekaterina A Anedchenko; Tatiana T Kondratieva; George S Krasnov; Alexei A Dmitriev; Veronika I Zabarovska; Tatiana V Pavlova; Vladimir I Kashuba; Michael I Lerman; Eugene R Zabarovsky
Journal:  BMC Cancer       Date:  2010-03-01       Impact factor: 4.430

4.  Novel tumor suppressor candidates on chromosome 3 revealed by NotI-microarrays in cervical cancer.

Authors:  Vera N Senchenko; Natalia P Kisseljova; Tatyana A Ivanova; Alexey A Dmitriev; George S Krasnov; Anna V Kudryavtseva; Grigory V Panasenko; Evgeny B Tsitrin; Michael I Lerman; Fyodor L Kisseljov; Vladimir I Kashuba; Eugene R Zabarovsky
Journal:  Epigenetics       Date:  2013-03-11       Impact factor: 4.528

5.  Concentration and Methylation of Cell-Free DNA from Blood Plasma as Diagnostic Markers of Renal Cancer.

Authors:  Inessa Skrypkina; Liudmyla Tsyba; Kateryna Onyshchenko; Dmytro Morderer; Olena Kashparova; Oleksii Nikolaienko; Grigory Panasenko; Sergii Vozianov; Alina Romanenko; Alla Rynditch
Journal:  Dis Markers       Date:  2016-09-20       Impact factor: 3.434

6.  Integrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma.

Authors:  Imran Nawaz; Li-Fu Hu; Zi-Ming Du; Khalid Moumad; Ilya Ignatyev; Tatiana V Pavlova; Vladimir Kashuba; Malin Almgren; Eugene R Zabarovsky; Ingemar Ernberg
Journal:  Oncotarget       Date:  2015-10-13

7.  Differential transmission of the molecular signature of RBSP3, LIMD1 and CDC25A in basal/ parabasal versus spinous of normal epithelium during head and neck tumorigenesis: A mechanistic study.

Authors:  Shreya Sarkar; Neyaz Alam; Syam Sundar Mandal; Kabita Chatterjee; Supratim Ghosh; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

8.  Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer.

Authors:  George S Krasnov; Grigory A Puzanov; Marina A Afanasyeva; Erdem B Dashinimaev; Khava S Vishnyakova; Artemy D Beniaminov; Alexei A Adzhubei; Tatiana T Kondratieva; Yegor E Yegorov; Vera N Senchenko
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

9.  Overexpression of EGFR in head and neck squamous cell carcinoma is associated with inactivation of SH3GL2 and CDC25A genes.

Authors:  Guru Prasad Maiti; Pinaki Mondal; Nupur Mukherjee; Amlan Ghosh; Susmita Ghosh; Sanjib Dey; Jayanta Chakrabarty; Anup Roy; Jaydip Biswas; Susanta Roychoudhury; Chinmay Kumar Panda
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

10.  NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.

Authors:  Vladimir Kashuba; Alexey A Dmitriev; George S Krasnov; Tatiana Pavlova; Ilya Ignatjev; Vasily V Gordiyuk; Anna V Gerashchenko; Eleonora A Braga; Surya P Yenamandra; Michael Lerman; Vera N Senchenko; Eugene Zabarovsky
Journal:  Int J Mol Sci       Date:  2012-10-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.